Ocata Therapeutics, Inc. 4
4 · Ocata Therapeutics, Inc. · Filed Nov 10, 2015
Insider Transaction Report
Form 4
Lanza Robert
Chief Scientific Officer
Transactions
- Sale
Common Stock
2015-11-10$8.36/sh−10,000$83,600→ 206,509 total - Sale
Common Stock
2015-11-10$8.36/sh−10,000$83,600→ 196,509 total - Sale
Common Stock
2015-11-10$8.25/sh−15,000$123,750→ 216,509 total
Footnotes (1)
- [F1]Shares sold pursuant to a 10b5-1 Plan.